13696-24-7

Upstream product

• 3156-41-0 1-nitro-4-(2-nitrovinyl)benzene 
• 555-16-8 4-nitrobenzaldehdye 
• 5881-57-2 2-methyl-4-(4-nitro-phenyl)-pyrrole-3-carboxylic acid ethyl ester 

Downstream Products

• 1312226-28-0 C₂₀H₁₅N₃O₃ 
• 1312226-30-4 3-[[3-(4-aminophenyl)-5-methyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-2H-indol-2-one 
• 1312226-32-6 C₂₀H₁₄N₄O₅ 
• 1312226-34-8 5-amino-3-[[3-(4-aminophenyl)-5-methyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-2H-indol-2-one 
• 1312226-36-0 3-[[3-[4-[(2-aminoethyl)amino]phenyl]-5-methyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-2H-indol-2-one 

Relevant academic research and scientific papers

Virtual screening and further development of novel ALK inhibitors

Anaplastic lymphoma kinase (ALK) has been in the spotlight in recent years as a promising new target for therapy of non-small-cell lung cancer (NSCLC). Since the identification of the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion gene in some NSCLC patients was reported in 2007, various research groups have been seeking ALK inhibitors. Above all, crizotinib (PF-02341066) has been under clinical trial, and its therapeutic efficacy of inhibiting ALK in NSCLC has been reported. Among anticancer drugs, drug resistance appears frequently necessitating various kinds of inhibitors. We identified novel ALK inhibitors by virtual screening from the public chemical library collected by the Chemical Biology Research Initiative (CBRI) at the University of Tokyo, and inhibitors that are more potent were developed.